Medtronic: The First Rival in Twenty-Five YearsNarrow moat

Medtronic's Hugo received FDA clearance for urologic procedures, including prostate removal, on 3 December 2025¹. It is the first robotic system for soft-tissue surgery brought to the United States by a large medical device company since Intuitive arrived more than two decades earlier.

The choice of indication is not accidental. Urology — prostatectomy in particular — is where robotic assistance is most clearly superior to the alternatives, where the clinical evidence is strongest, and where robotic penetration is already high. It is the easiest place to be credible. Medtronic has said it plans to extend to general surgery and gynecology next, announced positive results from a pivotal hernia repair study in September 2025, and began a United States gynecological trial in October.

What Medtronic brings that a start-up cannot is the thing Intuitive spent twenty-seven years building: presence. It sells into the same hospitals, employs representatives who are already in the same operating rooms, and can fund a robotics programme indefinitely out of businesses that are already profitable. It does not disclose its installed base, and the United States clearance it holds covers urology alone.

What it does not have is the accumulated clinical evidence, the trained surgeon population, the breadth of cleared indications, or the instrument portfolio. Those are years of work, not quarters.

For Intuitive, the immediate consequence is not lost share; it is the end of a negotiating position. A hospital administrator can now ask for a price, and the answer has to be a number rather than a shrug.

Watch Intuitive's average selling price, which rose to about $1.60 million in 2025². That is the cleanest read on whether a second supplier has changed anything yet, and so far it says no.